If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840. That answer will be terrible if you did buy into Pfizer then as it reflects a loss, not a gain -- of about 16% -- yikes! Annualized, ...
motleyfoolusx:pfe
With the new financial year under way, Iâve been looking for stocks to buy. And Iâve got things moving with a pair of dividend shares look like a bargain to me. Neither is a UK stock, which is unusual for me. But a delay to interest rate cuts across the Atlantic has created some opportunities in ...
motleyfoolukusx:pfeusx:o
Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to equally outsized windfalls. But for investors, it could still be a great pickup once a few of the loftier expectations ...
motleyfoolusx:pfe
Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have resulted in a lot of investors simply taking a pass on this top healthcare stock. But could that be a mistake, ...
motleyfoolusx:pfe
Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in high-yield dividend stocks, primarily because fund managers tend to aggressively purchase high-yield dividend ...
motleyfoolusx:pfeusx:t
Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). Keith Speights (AbbVie): What's ...
motleyfoolusx:gildusx:pfeusx:abbv
No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as governments rushed to buy millions of doses of their respective vaccines. However, this tailwind came to ...
motleyfoolusx:mrnausx:pfe
Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks. Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics (NASDAQ: AXSM), CRISPR Therapeutics (NASDAQ: CRSP), and Pfizer (NYSE: PFE) as top picks for investors ...
motleyfoolusx:pfeusx:crspusx:axsm
If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As long as the dividend remains sustainable, buying a dividend stock on a dip in price or near a low can be an ...
motleyfoolusx:pfe
The stock market is at record levels these days, but one company that isn't reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant are down 28% over the past 12 months as investors grow concerned about its long-term growth prospects. The company is in the midst of a transition as ...
motleyfoolusx:pfe
